麗珠醫藥(01513.HK)向麗珠生物增資
麗珠醫藥(01513.HK)公布,已辦理完畢其股東變更和註冊資本增加的商事變更登記備案工作並取得新的《營業執照》。本次變更完成後,麗珠生物的股東變更為公司、健康元及海南麗生聚源投資合夥企業(有限合夥),麗珠生物的註冊資本增加至6.67億元人民幣。
另外,公司、健康元、麗生聚源、YF、麗珠香港、麗珠單抗、卡迪及麗珠生物簽訂了增資協議,由公司與YF分別以9,829.93萬美元及5,000萬美元,認購麗珠生物之增加註冊資本,完成後,麗珠生物註冊資本由6.67億元人民幣,增至8.89億元人民幣。
YF認購事項完成後,麗珠生物將分別由公司、健康元、YF及麗生聚源持有51%、33.07%、8.43%及7.5%。
同時,麗珠香港同意轉讓而麗珠生物同意收購麗珠單抗100%的股權,涉資14.8億元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.